ES2166748T3 - Represor multivalente de la funcion genica. - Google Patents

Represor multivalente de la funcion genica.

Info

Publication number
ES2166748T3
ES2166748T3 ES90109892T ES90109892T ES2166748T3 ES 2166748 T3 ES2166748 T3 ES 2166748T3 ES 90109892 T ES90109892 T ES 90109892T ES 90109892 T ES90109892 T ES 90109892T ES 2166748 T3 ES2166748 T3 ES 2166748T3
Authority
ES
Spain
Prior art keywords
viral
htlv
hiv
rev
transdominant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90109892T
Other languages
English (en)
Inventor
Helmut Bachmayer
Ernst Boehnlein
Bryan R Cullen
Warner C Greene
Joachim Hauber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Duke University
Original Assignee
Novartis AG
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898915602A external-priority patent/GB8915602D0/en
Priority claimed from GB898924396A external-priority patent/GB8924396D0/en
Application filed by Novartis AG, Duke University filed Critical Novartis AG
Application granted granted Critical
Publication of ES2166748T3 publication Critical patent/ES2166748T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN REPRESORES TRANSDOMINANTES DE EXPRESION FENOTIPICA DE GENES VIRICOS DERIVADOS DEL GEN "REV" PRODUCTO DE VIH-1 O DEL GEN "REX" PRODUCIDO POR EL VHTL-1 Y MUTACIONES GENETICAS CORRESPONDIENTES, QUE TIENEN LA CAPACIDAD DE REPRIMIR LA FUNCION REV EN VIH-1 Y/O LA FUNCION REX EN VHTL-I Y VHTL-II. SE HAN USADO ANALISIS DE EXPRESIONES DE GENES TRANSITORIOS DE UNA SERIE DE MUTACIONES DE ELIMINACIONES Y DE SIGNIFICADO ERRONEO. SE HA ENCONTRADO QUE ALGUNAS DE ESTAS MUTACIONES REPRIMEN TANTO LA FUNCION REV COMO LA REX Y SON POR ELLO ACTIVOS EN MAS DE UNA ESPECIE VIRICA. LAS MUTACIONES VIRICAS TRANSDOMINANTES REPRESENTAN UNA PROMESA DE UNA NUEVA CLASE DE AGENTES ANTI VIRICOS. SE PUEDEN USAR EXPRESIONES CELULARES DE ESTOS INHIBIDORES TRANSDOMINANTES TANTO EN INJERTOS TERAPEUTICOS COMO EN INMUNIZACION INTRACELULAR PARA PROTEGER CELULAS CONTRA LOS PERNICIOSOS EFECTOS DE VIRUS, COMO POR EJEMPLO LA INFECCION DEL VIH-1.
ES90109892T 1989-05-25 1990-05-23 Represor multivalente de la funcion genica. Expired - Lifetime ES2166748T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35687889A 1989-05-25 1989-05-25
GB898915602A GB8915602D0 (en) 1989-07-07 1989-07-07 Multivalent repressor of gene function
GB898924396A GB8924396D0 (en) 1989-10-30 1989-10-30 Multivalent repressor of gene function
US44267089A 1989-11-29 1989-11-29

Publications (1)

Publication Number Publication Date
ES2166748T3 true ES2166748T3 (es) 2002-05-01

Family

ID=27450368

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90109892T Expired - Lifetime ES2166748T3 (es) 1989-05-25 1990-05-23 Represor multivalente de la funcion genica.

Country Status (13)

Country Link
EP (1) EP0406557B1 (es)
JP (2) JP3126378B2 (es)
KR (1) KR100215949B1 (es)
AT (1) ATE207122T1 (es)
AU (2) AU648256B2 (es)
CA (1) CA2032158C (es)
DE (1) DE69033829T2 (es)
DK (1) DK0406557T3 (es)
ES (1) ES2166748T3 (es)
FI (1) FI110437B (es)
HU (2) HU217091B (es)
IL (1) IL94482A (es)
WO (1) WO1990014427A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649502B2 (en) * 1990-10-17 1994-05-26 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Molecular clones of HIV-1 and uses thereof
US5534408A (en) * 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
US5650306A (en) * 1993-06-07 1997-07-22 University Of Michigan Recombinant nucleic acids for inhibiting HIV gene expression
AU7263994A (en) * 1993-08-06 1995-02-28 Kai Juhani Ernst Krohn Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses
US5981258A (en) * 1993-12-13 1999-11-09 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an antiviral effect
US6228369B1 (en) 1993-12-13 2001-05-08 Transgene S.A. Composition of trans-dominant variants of viral proteins for obtaining an anti-viral effect
FR2713651B1 (fr) * 1993-12-13 1996-04-19 Transgene Sa Nouvelle composition pour un effet antiviral.
CN1209875A (zh) 1996-01-26 1999-03-03 维科公司 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
JP2000514284A (ja) * 1996-06-06 2000-10-31 ノバルティス・アクチエンゲゼルシャフト Ｓａｒエレメントを有するベクター
EP0914423A2 (en) * 1996-06-06 1999-05-12 Novartis AG Inhibition of hiv-1 replication by antisense rna expression
CA2355836A1 (en) * 1998-12-22 2000-06-29 Subsidiary No. 3, Inc. Genetic suppressor elements against human immunodeficiency virus
AU2493300A (en) * 1999-01-06 2000-07-24 Regents Of The University Of California, The Modulation of hiv replication using sam68
US7300790B2 (en) 2003-01-23 2007-11-27 Iogenetics, Llc Transgenic animals expressing transdominant negative retroviral nucleic acids and proteins
JP5653549B1 (ja) 2014-05-30 2015-01-14 株式会社松風 イオン徐放性歯科用レジン系仮封材組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935372A (en) * 1986-05-20 1990-06-19 Dana Farber Cancer Institute Art nucleotide segments, vectors, cell lines methods of preparation and use

Also Published As

Publication number Publication date
DK0406557T3 (da) 2002-02-11
JP3159671B2 (ja) 2001-04-23
ATE207122T1 (de) 2001-11-15
KR920701440A (ko) 1992-08-11
JPH04500009A (ja) 1992-01-09
HUT56135A (en) 1991-07-29
EP0406557A2 (en) 1991-01-09
JPH10165188A (ja) 1998-06-23
AU5738890A (en) 1990-12-18
JP3126378B2 (ja) 2001-01-22
HU211530A9 (en) 1995-11-28
FI910371A0 (fi) 1991-01-24
HU217091B (hu) 1999-11-29
EP0406557B1 (en) 2001-10-17
DE69033829T2 (de) 2002-04-04
AU678478B2 (en) 1997-05-29
WO1990014427A3 (en) 1991-01-10
CA2032158C (en) 2009-09-15
IL94482A0 (en) 1991-03-10
AU6757394A (en) 1994-11-17
FI110437B (fi) 2003-01-31
AU648256B2 (en) 1994-04-21
KR100215949B1 (ko) 1999-08-16
DE69033829D1 (de) 2001-11-22
HU904245D0 (en) 1991-06-28
WO1990014427A2 (en) 1990-11-29
EP0406557A3 (en) 1991-05-02
CA2032158A1 (en) 1990-11-26
IL94482A (en) 2003-09-17

Similar Documents

Publication Publication Date Title
ES2166748T3 (es) Represor multivalente de la funcion genica.
TR199900848T2 (xx) Oksadiazoller, elde edilmeleri ve ila� olarak kullan�mlar�.
ES2081370T3 (es) Gen y proteina de bacillus thuringiensis, y su utilizacion.
HUP0203075A2 (hu) Aromás diamidszármazékok és sóik, ezeket tartalmazó, a mezőgazdaságban és a kertészetben alkalmazható készítmények és ezek alkalmazása
ES2063183T3 (es) Oligonucleotidos antisentido para la inhibicion de la secuencia diana del transactivador (tar) y de la sintesis de la proteina transactivadora (tat) de hiv-i y su uso.
BG102048A (en) Tetrahydrofuran-containing sulphonamides as aspartylprotease inhibitors
DE69201564T2 (de) Verwendung von metalloxidmanopigmenten zum schutz von haarkeratin vor äusseren einflüssen, insbesondere sonnenlicht, verfahren zum schutz des haares und gelzusammensetzung unter verwendung dieser nanopigmente.
DE69301017T2 (de) Von perhalogenierten sultonen abgeleiteten monomere,sowie aus diesen monomeren hergestellte polymere
DE69019533D1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
FI853648L (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva 4,5-dihydro-4-okso-2-/(2-trans-fenylcyklopropyl) amino/-3-furankarboxylsyror och derivat daerav.
DK0789764T3 (da) Ny familie af proteaseinhibitorer og andre biologisk aktive substanser
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
FR2732978B1 (fr) Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
IT8019677A0 (it) Apparato per manipolare una pluralita' di articoli.
GR1000639B (el) Μεθοδος για την παρασκευη μιας συνθεσεως για την αντιμετωπιση της αμυγδαλιτιδας.
EP0474797A4 (en) Protein having a transactivating property, vectors expressing this protein, cell lines, and uses thereof
MY104777A (en) Benzoxazine dyes
SU872166A1 (ru) Способ восстановлени изношенной поверхности изделий
FR2643368B1 (fr) Nouveaux derives du glycerol, leur procede de preparation, compositions reticulantes en contenant, et leur utilisation dans l'industrie textile
TR23745A (tr) 1-dimetilkarbomoil-3-suebstituee 1h-1.2.4-triazoller
Michailova Polytene chromosomes of different subfamilies of family Chironomidae, Diptera
SU852578A1 (ru) Способ воздействи на процессуСАдКи глиНиСТыХ гРуНТОВ
DE69434019D1 (de) Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung
Buchteeva THE CHARACTERISTICS OF THE KARYOTYPE AND INVERSION POLYMORPHISM OF CHIRONaMUS PLUMOSUS VAR FLAVEOLUS MEIG FROM THE EASTERN SIBERIA
DK99588A (da) 2-(aminoalkythio)methyl-1,4-dihydropyridin-forbindelser, en fremgangsmaade til deres fremstilling og farmaceutiske midler indeholdende dem